Delanzomib

Delanzomib (CAS 847499-27-8), also referenced as CEP-18770, is a proteasome inhibitor developed for oncology research applications.

Where is Delanzomib used?

• Hematological malignancy research: targets the 20S proteasome complex
• Drug discovery: reference compound for benchmarking novel proteasome inhibitor candidates
• Combination therapy research: alongside agents targeting complementary oncogenic pathways
• Biotechnology laboratories procure it as an analytical standard for assay development and biomarker validation studies.

Good to know: Also referenced as CT-47098, a catalog identifier used by suppliers in the life sciences sector.

Commercial specifications

• High purity (≥98% by HPLC)
• Material manufactured under GMP standards can be sourced for investigational use
• Documentation packages support regulatory submissions and compliance with international safety protocols